u-s-oncologists-are-not-satisfied-with-wishing-nsclc-more-weapons
2024-03-08

U.S. oncologists are not satisfied with wishing NSCLC more weapons

U.S. oncologists are not satisfied with the treatment of NSCLC, and they hope for more treatments, more weapons for different patients, more research on managing complications, and more tools to predict treatment response.

Non-small cell lung cancer-

Center for Cancer Research (CRI; Cancer Research Institute) and Regeneron and consulting firm Harris conducted a survey of 250 oncologists treating non-small cell lung cancer (NSCLC) and the findings showed that there is still a considerable unmet need for NSCLC. Approximately 30% believe that more immunotherapy is needed for advanced NSCLC, and only 17% of physicians say that the available treatments are excellent.

About 88% of physicians believe that more research is needed in patients with advanced NSCLC and comorbidities, about 45% of these patients have hypertension or lung disease, and about two-thirds of respondents say they do not have adequate weapons for their cardiovascular disease.

Treatment options for patients with poor health?

  • Physicians also say more resources are needed for patients with brain metastases, people of color, and people over the age of 70. Chemotherapy is still part of the treatment regimen for patients with advanced NSCLC, but for patients with less healthy conditions, milder drugs, fewer drugs or a replacement with radiotherapy are required.

Regeneron is looking for a gap in the market

  • NSCLC is an area of regeneron development, and their PD-1 inhibitor libtayo is now working in the NSCLC field in addition to CSCC, and the company is also evaluating the efficacy of its EGFRxCD28 bispecific antibody in EGFR-mutated NSCLC.
  • CSCC: Cutaneous squamous cell carcinoma
  • EGFR: Epidermal growth factor receptor

–

The content of this article has been authorized by Pharmaceutical Statistical Insights to PatientForce™ (Caihong Integrated Marketing Co., Ltd. / Unified Number: 27903403), all of which are jointly owned by PatientForce™ and Pharmaceutical Statistical Insights in accordance with the law.

Resources

Article Search

Latest articles